Navigation Links
Singulex Advances Conversation on Personalized Medicine

HALF MOON BAY, Calif., May 13 /PRNewswire/ -- Personalized medicine is changing the face of healthcare. Currently, pharmacogenomic tests can help physicians determine the right dosing schedule for warfarin or to predict the potential for adverse drug reactions. In the near future, health professionals will leverage protein-based biomarkers to predict drug safety and efficacy and to detect disease earlier.

Singulex Inc., a company focused on advancing technologies for early disease detection, today announced that its CEO, Philippe Goix, Ph.D., is chairing a panel on personalized medicine at the Think Tomorrow Today Summit, sponsored by ThinkPanmure. Participants on the panel, entitled "Just for Me: Personalized Medicine," include Michael McKenna, Ph.D., CSO of Tethys Biosciences and Kathryn Phillips, Ph.D., professor of health economics & health services research at UCSF.

"While pharmacogenomics represent much of the current activity in personalized medicine, they are only the tip of the iceberg," said Philippe Goix, CEO of Singulex. "The utility of protein biomarkers could soon eclipse that of pharmacogenomics, allowing much earlier disease detection and also enabling pharmaceutical companies to identify what patient populations will respond to their drug and then to monitor those patients to measure disease regression."

Singulex has pioneered technology that increases the clinical utility of biomarkers using immunoassay technologies. Through collaborations with pharmaceutical and biotechnology companies and academic researchers, the company has shown specifically that the biomarker c Troponin I (cTnI), a validated biomarker for cardiac necrosis, can be detected in healthy people. Singulex can also measure small changes in cTnI levels that indicate stress to the heart, such as during treadmill stress tests, which other technologies cannot do.

About Singulex

Singulex develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company's commercial digital molecule detection platform, the Erenna(TM) Immunoassay System. Singulex's research and development facilities are located at the Center for Emerging Technologies in St Louis, Missouri, and the company's commercial operations are based in Alameda, California. To learn more about Singulex, please visit us at

SOURCE Singulex Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Singulex Announces Presentation on Monitoring of Cardiac Biomarker to Assess Transient Myocardial Ischemia at the American Heart Association Scientific Sessions
2. TGrid 5.0 Advances Automatic, High-Quality Meshing Tools for Increased Productivity
3. Imaging Advances Map Brain Areas Affecting Mood
4. Recent Advances Make Sunscreen More Effective and Easier to Use
5. Treatment advances for fibroids, menopause
6. Breast reconstruction advances fix distortions left by lumpectomy
7. Breast Reconstruction Advances Fix Distortions Left by Lumpectomy
8. Minnesota partnership advances potential MS therapy
9. Top Policy Experts to Debate Link Between Rising Health Care Costs and Advances in Medical Technology, Wednesday, April 16, 2008, From 8:30 - 10:00 A.M., at DCs National Press Club
10. Latest Advances in Diabetes Research to be Presented in San Francisco, California at Worlds Largest Diabetes Conference, June 6-10, 2008
11. DNV Healthcare Advances in Bid to Accredit Hospitals
Post Your Comments:
(Date:12/1/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... in the 1980s we have seen vast improvements in scientific research and discoveries, ... significant strides, providing increased hope and relief to those affected by HIV/AIDS. Mediaplanet’s ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Imaging Inc. (“Visage”), a wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), ... at the Radiological Society of North America (RSNA) 2015 annual meeting through December ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and ... to the devices for sale in the United States. Clarity is a Superior ... nm Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... and SACC-USA through membership and leadership since 2008. Gary Bruce, President of PartnerTech ... . Gary has spent a significant amount of time in Sweden since joining ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... , December 1, 2015 ... new market research report "Nucleic Acid Labeling Market by ... Nick Translation, Random Primer, In Vitro Transcription, Reverse Transcription, ... published by MarketsandMarkets, The global market is expected to ... Million in 2015, growing at a CAGR of 8.65%. ...
(Date:12/1/2015)... , December 1, 2015 Russia ... clinical trials. 70% of new drugs registered in Europe ... Russia . --> Russia has always been ... of new drugs registered in Europe in 2015 ... --> Russia has always been a country ...
(Date:12/1/2015)... 2015 Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... announced today that the company will present at the LD ... at the Luxe Sunset Boulevard Hotel in Los ... Relmada Therapeutics, will present on Thursday, December 3, at 9:00 ... . Please register at least 10 minutes prior to the ...
Breaking Medicine Technology: